Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Traslation]

February 14, 2022

To: Shareholders

Company Name: Renascience Inc.

Name of Representative: Koji Naito, President & CEO

(Code: 4889 TSE Mothers)

Inquiries: Kazuhiro Ikeda, Director, CFO

Notice Concerning Recording of Non-Operating Expenses

The Company has recorded non-operating expenses for the nine months ended December 31, 2022 (April 1, 2021 to December 31, 2021), as described below.

Particulars

1. Details of non-operating expenses

Interest expenses of 5,366 thousand yen were recorded in connection with borrowings from banks.

2. Outlook for the future

This matter is reflected in the "Financial Results for the Third Quarter of the Fiscal Year Ended March 31, 2022 [Under Japanese GAAP] (Non-Consolidated) "released today.

End